Factors influencing patient's perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study

被引:4
|
作者
Debourdeau, P. [1 ]
Arvers, P. [2 ]
Hij, A. [3 ,4 ,5 ]
Bennani, H. [6 ]
Desauw, C. [7 ]
Falvo, N. [8 ]
Ghiringhelli, F. [9 ]
Hamade, A. [10 ]
Vedrine, L. [11 ]
Farge, D. [3 ,4 ,5 ]
机构
[1] Inst St Catherine, Unite Soins Support, 250 Chemin Baigne Pieds CS 80005, F-84918 Avignon, France
[2] Univ Grenoble Alpes, Lab Interuniv Psychol, BP 47, F-38040 Grenoble 9, France
[3] Hop St Louis, AP HP, Unite Med Interne Malad Autoimmunes & Pathol Vasc, 1 Ave Claude Vellefawc, F-75010 Paris, France
[4] Univ Paris 07, Paris, France
[5] Grp Francophone Thrombose & Canc, Paris, France
[6] Hop Rene Huguenin, Inst Curie, 35 Rue Daily, F-92210 St Cloud, France
[7] Hop Claude Huriez, Serv Oncol, Rue Michel Polonowski, F-59037 Lille, France
[8] Hop Bocage, Serv Med Interne, 2 Blvd Marechal Lattre Tassigny, F-21000 Dijon, France
[9] Ctr Anti Cancereux Ctr GF Leclerc, 1 Rue Prof Mar, F-21000 Dijon, France
[10] Hop Emile Muller, Unite Pathol Vasc, 20 Rue Docteur Laennec, F-68070 Mulhouse 10, France
[11] Hop Amer Paris, Serv Doncol, 63 Blvd Victor Hugo, F-92200 Neuilly Sur Seine, France
关键词
LMWH; Acceptability; Cancer; Experience; Quality of life; Venous thromboembolism; VENOUS THROMBOEMBOLISM PROPHYLAXIS; CLINICAL-PRACTICE GUIDELINES; ANTICOAGULATION THERAPY; ATRIAL-FIBRILLATION; PALLIATIVE CARE; GUIDANCE; PREVENTION; ADHERENCE;
D O I
10.1007/s00520-019-04815-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Our objective was to compare patient's expectations to their experience and to identify factors predictive of patient's perception of long-term LMWH for the treatment of cancer-associated thrombosis (CAT). Methods Results from the validated Perception Anticoagulant Treatment Questionnaires (PACTQ) completed before inclusion (PACTQ1 for expectations) and at the end (PACTQ2 for convenience and satisfaction) of the 6-month TROPIQUE study were studied with principal component analysis. Possible predictive factors of improved perception of LMWH treatment were analyzed with the Kruskall-Wallis test. Results Among 409 included patients treated with LMWH, 269 PACT-Q1 and 139 PACT-Q2 were evaluable for treatment perception. Patients had high expectations (A1-A7 score of 26.7 +/- 3.5, max = 35). Treatment cost (A7 = 1.90 +/- 1.31) and concern about a mistake in anticoagulation (A5 = 1.93 +/- 1.12) had little importance while LMWH treatment was considered easy to use (A4 = 4.20 +/- 0.93). Six-month treatment with LMWH was associated with a high rate of convenience (B1-B11, C1-C2 = 55.1 +/- 8.38, max = 65) and a high satisfaction score (D1-D7 = 25.1 +/- 4.32, max = 35). Patients' confidence in treatment and perception of possible LMWH side effects were moderate while perception of autonomy and independence significantly improved at the end of the study compared to inclusion. PACT-Q2 satisfaction score was low in patients who experienced bleeding (PACT-Q2 24.1 +/- 3.3 vs. 25.1 +/- 4.3). LMWH twice daily tended to be found less convenient compared than once daily (53.3 +/- 7.2 vs. 55.0 +/- 8.3). Conclusion CAT patients had a good perception of the 6-month LMWH treatment when comparing expectations and experience. Using a quantitative scale validated in the general population for VTE and subcutaneous injection and including a large number of patients, bleeding complications and LMWH twice daily were associated with a nonsignificant trend towards a worsen perception.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 33 条
  • [21] Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis
    Kang, Wei
    Peng, Kuan
    Yan, Vincent K. C.
    Al-Badriyeh, Daoud
    Lee, Shing Fung
    Yiu, Hei Hang Edmund
    Wei, Yue
    Li, Silvia T. H.
    Ye, Xuxiao
    El Helali, Aya
    Lam, Ka On
    Lee, Victor H. F.
    Wong, Ian C. K.
    Chan, Esther W.
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2024, 17 (01)
  • [22] Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)
    Otero, Remedios
    Solier-Lopez, Aurora
    Sanchez-Lopez, Veronica
    Oto, Julia
    Arellano, Elena
    Marin, Samira
    Jara-Palomares, Luis
    Elias, Teresa
    Asencio, Maria Isabel
    Blasco-Esquivias, Isabel
    Rodriguez de la Borbolla, Maria
    Sanchez-Diaz, Jose Maria
    Real-Dominguez, Macarena
    Garcia-Cabrera, Emilio
    Rodriguez-Martorell, Francisco Javier
    Medina, Pilar
    CANCERS, 2022, 14 (11)
  • [23] Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials
    Frere, Corinne
    Farge, Dominique
    Schrag, Deborah
    Prata, Pedro H.
    Connors, Jean M.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [24] Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis
    Connell, Nathan T.
    Abel, Gregory A.
    Connors, Jean M.
    THROMBOSIS RESEARCH, 2017, 150 : 53 - 58
  • [25] Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants
    Iorio, A
    Guercini, F
    Pini, M
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (09) : 1906 - 1913
  • [26] A Randomised Open-Label Trial Comparing Long-term Sub-Cutaneous Low-Molecular-weight Heparin Compared with Oral-Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis
    Romera, A.
    Cairols, M. A.
    Vila-Coll, R.
    Marti, X.
    Colome, E.
    Bonell, A.
    Lapiedra, O.
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2009, 37 (03) : 349 - 356
  • [27] A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)
    Noble, Simon I.
    Nelson, Annmarie
    Fitzmaurice, David
    Bekkers, Marie-Jet
    Baillie, Jessica
    Sivell, Stephanie
    Canham, Joanna
    Smith, Joanna D.
    Casbard, Angela
    Cohen, Ander
    Cohen, David
    Evans, Jessica
    Fletcher, Kate
    Johnson, Miriam
    Maraveyas, Anthony
    Prout, Hayley
    Hood, Kerenza
    HEALTH TECHNOLOGY ASSESSMENT, 2015, 19 (83) : 1 - +
  • [28] Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials
    Corinne Frere
    Dominique Farge
    Deborah Schrag
    Pedro H. Prata
    Jean M. Connors
    Journal of Hematology & Oncology, 15
  • [29] Long-term administration of a low-molecular-weight heparin contributed to successful treatment in a patient with primary mediastinal large B-Cell lymphoma and venous thromboembolism
    Mori, Akio
    Ibata, Makoto
    Mashiko, Shinobu
    Tsutsumi, Yutaka
    Masauzi, Nobuo
    Hashino, Satoshi
    Morioka, Masanobu
    Asaka, Masahiro
    Imamura, Masahiro
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2008, 14 (04) : 468 - 471
  • [30] Efficacy of Low-molecular-weight-heparin versus Vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: A systematic review of randomized controlled trials
    Louzada, Martha L.
    Majeed, Habeeb
    Wells, Philip S.
    THROMBOSIS RESEARCH, 2009, 123 (06) : 837 - 844